Sort by

Send to

Choose Destination

Search results

Items: 13


Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes.

Tsai IF, Kuo CP, Lin AB, Chien MN, Ho HT, Wei TY, Wu CL, Lu YT.

Respirology. 2016 Nov 23. doi: 10.1111/resp.12948. [Epub ahead of print]


Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.

Scagliotti G, Kang JH, Smith D, Rosenberg R, Park K, Kim SW, Su WC, Boyd TE, Richards DA, Novello S, Hynes SM, Myrand SP, Lin J, Smyth EN, Wijayawardana S, Lin AB, Pinder-Schenck M.

Invest New Drugs. 2016 Oct;34(5):625-35. doi: 10.1007/s10637-016-0368-1.


Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.

Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J.

J Clin Oncol. 2016 May 20;34(15):1764-71. doi: 10.1200/JCO.2015.64.5788.


Analysis of the immune response of human dendritic cells to Mycobacterium tuberculosis by quantitative proteomics.

Kuo CP, Chang KS, Hsu JL, Tsai IF, Lin AB, Wei TY, Wu CL, Lu YT.

Proteome Sci. 2016 Mar 8;14:5. doi: 10.1186/s12953-016-0095-8.


Bicyclol attenuates tetracycline-induced fatty liver associated with inhibition of hepatic ER stress and apoptosis in mice.

Yao XM, Li Y, Li HW, Cheng XY, Lin AB, Qu JG.

Can J Physiol Pharmacol. 2016 Jan;94(1):1-8. doi: 10.1139/cjpp-2015-0074.


Treatment Patterns and Health Care Resource use (Hcru) Associated with Repeatedly Treated Metastatic Squamous Cell Carcinoma of the Head and Neck (Scchn) in the United Kingdom (Uk).

Nash Smyth E, La E, Talbird S, Li L, Kaye JA, Lin AB, Bowman L.

Value Health. 2015 Nov;18(7):A450-1. doi: 10.1016/j.jval.2015.09.1136. No abstract available.


Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.

Doi T, Yoshino T, Shitara K, Matsubara N, Fuse N, Naito Y, Uenaka K, Nakamura T, Hynes SM, Lin AB.

Anticancer Drugs. 2015 Nov;26(10):1043-53. doi: 10.1097/CAD.0000000000000278.


Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates.

Chou DH, Webber MJ, Tang BC, Lin AB, Thapa LS, Deng D, Truong JV, Cortinas AB, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2401-6. doi: 10.1073/pnas.1424684112.


Medical therapy for glaucoma: what to add after a prostaglandin analogs?

Tanna AP, Lin AB.

Curr Opin Ophthalmol. 2015 Mar;26(2):116-20. doi: 10.1097/ICU.0000000000000134. Review.


Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.

Calvo E, Chen VJ, Marshall M, Ohnmacht U, Hynes SM, Kumm E, Diaz HB, Barnard D, Merzoug FF, Huber L, Kays L, Iversen P, Calles A, Voss B, Lin AB, Dickgreber N, Wehler T, Sebastian M.

Invest New Drugs. 2014 Oct;32(5):955-68. doi: 10.1007/s10637-014-0114-5.


Mesenchymal stem cells in regenerative medicine for musculoskeletal diseases: bench, bedside, and industry.

Wei CC, Lin AB, Hung SC.

Cell Transplant. 2014;23(4-5):505-12. doi: 10.3727/096368914X678328. Review.


A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.

Yin T, Lallena MJ, Kreklau EL, Fales KR, Carballares S, Torrres R, Wishart GN, Ajamie RT, Cronier DM, Iversen PW, Meier TI, Foreman RT, Zeckner D, Sissons SE, Halstead BW, Lin AB, Donoho GP, Qian Y, Li S, Wu S, Aggarwal A, Ye XS, Starling JJ, Gaynor RB, de Dios A, Du J.

Mol Cancer Ther. 2014 Jun;13(6):1442-56. doi: 10.1158/1535-7163.MCT-13-0849.


The top PDA resources for family physicians.

Lin AB.

Fam Pract Manag. 2006 Jul-Aug;13(7):44-6. No abstract available. Erratum in: Fam Pract Manag. 2006 Sep;13(8):24.

Items per page

Supplemental Content

Loading ...
Support Center